

Caspofungin Inhibits *Rhizopus oryzae* 1,3-β-D-Glucan Synthase, Lowers Burden in Brain Measured by Quantitative PCR, and Improves Survival at a Low but Not a High Dose during Murine Disseminated Zygomycosis

Ashraf S. Ibrahim,^{1,2*} Joel C. Bowman,³ Valentina Avanesian,¹ Keturah Brown,³
Brad Spellberg,^{1,2} John E. Edwards, Jr.,^{1,2} and Cameron M. Douglas³

Los Angeles Biomedical Research Institute at Harbor-University of California, Los Angeles, Medical Center, Torrance,¹
and University of California, Los Angeles, School of Medicine, Los Angeles,² California,
and Department of Human and Animal Infectious Disease Research,
Merck Research Laboratories, Rahway, New Jersey³

Received 7 July 2004/Returned for modification 5 September 2004/Accepted 1 October 2004

***Rhizopus oryzae* is the most common cause of zygomycosis, a life-threatening infection that usually occurs in patients with diabetic ketoacidosis. Despite standard therapy, the overall rate of mortality from zygomycosis remains >50%, and new strategies for treatment are urgently needed. The activities of caspofungin acetate (CAS) and other echinocandins (antifungal inhibitors of the synthesis of 1,3-β-D-glucan synthase [GS]) against the agents of zygomycosis have remained relatively unexplored, especially in animal models of infection. We found that *R. oryzae* has both an *FKS* gene, which in other fungi encodes a subunit of the GS synthesis complex, and CAS-susceptible, membrane-associated GS activity. Low-dose but not high-dose CAS improved the survival of mice with diabetic ketoacidosis infected with a small inoculum but not a large inoculum of *R. oryzae*. Fungal burden, assessed by a novel quantitative PCR assay, correlated with increasing inocula and progression of disease, particularly later in the infection, when CFU counts did not. CAS decreased the brain burden of *R. oryzae* when it was given prophylactically but not when therapy was started after infection. These results indicate that CAS has significant but limited activity against *R. oryzae* in vivo and demonstrates an inverse dose-response effect. The potential for CAS to play a role in combination therapy against zygomycosis merits further investigation.**

Zygomycosis is an infection caused by fungi of the class *Zygomycetes*, order *Mucorales*. Members of this order cause progressive, necrotic, and generally fatal infections in immunocompromised hosts, such as diabetics with ketoacidosis, neutropenic patients, patients taking corticosteroids, and patients with elevated available serum iron levels (12, 22, 28, 35). *Rhizopus oryzae* is the organism that is the most frequently isolated from patients with zygomycosis (22, 31).

The standard therapy for invasive zygomycosis consists of reversal of the underlying predisposing factors, widespread surgical debridement, and aggressive antifungal medication (12, 22, 35). Amphotericin B deoxycholate (AMB) remains the only antifungal agent approved for the therapy of invasive zygomycosis (12, 22, 35). Unfortunately, despite disfiguring surgical debridement and aggressive therapy with AMB, the overall rate of mortality from zygomycosis remains >50% (35), and it approaches 100% in patients with disseminated disease (20). New strategies for the treatment of zygomycosis are urgently needed.

The echinocandin class of antifungal antibiotics targets the synthesis of 1,3-β-D-glucan synthase (GS), the activity of which

is essential for the assembly of a functional cell wall in many fungi (4, 8). The enzyme is a multisubunit complex, which includes an integral membrane protein and a regulatory subunit, encoded by members of the *FKS* and *RHO1* gene families, respectively. Echinocandins such as caspofungin acetate (CAS) have activity against important fungal pathogens, including *Candida* and *Aspergillus* spp. (1, 4, 8). In contrast, limited in vitro studies have reported that echinocandins have high MICs for zygomycetes, *Fusarium* spp., and *Cryptococcus neoformans* (26, 29). Subsequent studies found that when CAS is combined with other drugs, such as AMB or calcineurin inhibitors, CAS demonstrated substantial in vitro activity against *Fusarium solani* and *C. neoformans* (2, 7). These studies prompted us to further investigate the in vitro and in vivo activities of CAS against *R. oryzae*. We report that *R. oryzae* has an *FKS* gene and that CAS inhibits GS activity in crude *R. oryzae* membrane preparations. Additionally, CAS demonstrates efficacy in vivo during disseminated *R. oryzae* infection in diabetic ketoacidotic mice.

(This work was presented in part at the 42nd and 43rd Interscience Conferences on Antimicrobial Agents and Chemotherapy, San Diego, Calif., 27 to 30 September 2002, and Chicago, Ill., 14 to 17 September 2003, respectively.)

* Corresponding author. Mailing address: Division of Infectious Diseases, St. John's Cardiovascular Research Center, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Bldg. RB2, 1124 West Carson St., Torrance, CA 90502. Phone: (310) 222-3813. Fax: (310) 782-2016. E-mail: ibrahim@labiomed.org.

MATERIALS AND METHODS

Organism. The *R. oryzae* 99-880 isolate and conditions for growth were described previously (21). Spores were counted and adjusted to the desired con-

centration in endotoxin-free phosphate-buffered saline (PBS). The viability of the spores was >95%, as determined by CFU quantitation. Susceptibility testing was performed in RPMI 1640 buffered with morpholinepropanesulfonic acid (0.165 M; pH 7.0), and the result was read after 24 h at 35°C. The minimum effective concentration of CAS was determined in this medium with the endpoint described previously (27).

Genomic DNA isolation, PCR, and Southern hybridization. Approximately 10^5 *R. oryzae* spores were inoculated into 5 ml of GYEP medium (5% glucose, 0.1% yeast extract, 0.1% peptone) and incubated overnight at 37°C, and the genomic DNA was purified from the mycelium, as described previously (37).

A pileup of amino acid sequences predicted from the *FKS* genes of *Aspergillus fumigatus*, *Candida albicans*, *C. neoformans*, and *Saccharomyces cerevisiae* was performed; and degenerate primers homologous to conserved regions in the pileup were designed. The primer sequences are as follows: sense primer, 5'-AAYCAIGAYAAITAITYTIGA-3'; antisense primer, 5'-TTICCRCAITGITAITA YTC-3' (where I is inosine, Y is C or T, and R is A or G). PCR products were cloned with the pCR2.1 TOPO TA cloning kit (Invitrogen, Carlsbad, Calif.) and sequenced with a Big Dye Terminator (version 3.0) cycle sequencing kit (Applied Biosystems, Foster City, Calif.). Sequencing reactions were run on an ABI PRISM 3100 genetic analyzer (Applied Biosystems), according to the instructions of the manufacturer.

For Southern blot analysis, approximately 15 µg of *R. oryzae* genomic DNA was digested with restriction enzymes, subjected to gel electrophoresis, and transferred to a Nytran membrane (Schleicher & Schuell, Keene, N.H.). The *R. oryzae* PCR product was radiolabeled with random primers (Invitrogen); hybridization and washing of the blot were performed at high stringency, and the signals were visualized by autoradiography.

Characterization of *R. oryzae* GS activity. Crude *R. oryzae* membranes containing GS activity were isolated from mycelia grown in liquid culture. YME medium (0.4% yeast extract, 1.0% malt extract, 0.4% dextrose) was inoculated with 10^6 *R. oryzae* 99-880 spores per ml of culture, and the spores were incubated for 18 h at 37°C with shaking at 220 rpm. The mycelia were harvested by filtration over a Miracloth and rinsed several times with water. Excess water was squeezed from the fungal mass, and the wet weight was determined. The mycelia were resuspended in 3 ml of extraction buffer (50 mM HEPES [pH 7.5], 1 mM EDTA, 1 mM dithiothreitol, 10% glycerol, complete protease inhibitor [Roche, Indianapolis, Ind.]) per g (wet weight) and disrupted by passage (two times) through a prechilled French press at 12,000 lb/in². Unbroken cells were removed by centrifugation at 2,500 × g for 10 min, and the crude membranes were collected by centrifugation at 100,000 × g for 1 h. The membrane pellet was resuspended in storage buffer (50 mM HEPES [pH 7.5], 1 mM EDTA, 1 mM dithiothreitol, and 20% glycerol containing protease inhibitors) by using a Dounce homogenizer, and the suspension was stored at -80°C. The membrane protein concentration was determined from a sample solubilized in detergent (0.03% sodium deoxycholate) and precipitated with trichloroacetic acid (TCA) (11) by using a Micro-BCA protein assay kit (Pierce, Rockford, Ill.).

GS activity was measured as described previously (11). Each 100-µl reaction mixture contained 30 µg of crude membranes, 50 mM HEPES (pH 7.5), 10% glycerol, 3.5 mg of bovine serum albumin per ml, 25 mM KF, 1 mM EDTA, 25 µM guanosine 5'-[gamma-thio]triphosphate (GTPγS), 0.5 mM UDP-glucose, and 0.3 µCi of [³H]UDP-glucose (34 Ci/mmol; Amersham, Piscataway, N.J.). The reaction mixtures were incubated at 30°C for 4 h with gentle rocking, the reactions were stopped by the addition of 100 µl of ice-cold 20% TCA, and the product was collected on glass-fiber filters (Whatman; Fisher Scientific) and washed three times with water. The radiolabeled product was measured by liquid scintillation counting. For product characterization, the reactions were terminated by boiling for 2 min, and solubility in either 0.1 M acetic acid or 0.1 M NaOH or susceptibility to digestion with 1,3-β-D-glucanase (0.25 U of Zymolyase T-100; Seikagaku America, E. Falmouth, Mass.) was measured as described previously (11, 27). The 50% inhibitory concentration (IC₅₀) of CAS for GS was determined from a drug titration (100 to 0.002 µg of CAS per ml from a 10-mg/ml stock solution prepared in water) with Prism software (version 3.0; GraphPad, San Diego, Calif.).

Animal model. Male BALB/c mice (weight, ≥24 g; Harlan, San Diego, Calif.) were housed in groups of five mice each and were given irradiated feed and sterile water ad libitum. Animal studies were conducted in accordance with the National Institutes of Health guidelines for the care and use of laboratory animals.

Mice were rendered diabetic by administering streptozotocin (210 mg/kg of body weight), as described previously (21). This dose of streptozotocin caused diabetes in 80 to 90% of the injected mice (data not shown). Glycosuria and ketonuria were determined with keto-Diastix reagent strips (Bayer, Elkhart, Ind.) 7 days after streptozotocin treatment. Only mice that developed diabetes

with mild ketoacidosis (level of ketonuria, ≤5 mg/dl) were included in the study (39). A suspension of 0.2 ml of PBS containing *R. oryzae* spores in endotoxin-free PBS was injected into the lateral tail vein. To confirm the inoculum, dilutions were streaked on potato dextrose agar (PDA) plates, and the colonies were counted following 24 h of incubation at room temperature. After infection, the mice were randomly sorted into different treatment groups.

Drugs and therapy. AMB (Fungizone; Bristol-Myers Squibb) was given in 5% glucose at a dose of 1 mg/kg/day. CAS powder (Merck Research Laboratories) was dissolved daily in sterile water and was given at a total dose of 1, 5, or 10 mg/kg/day.

Drugs were administered intravenously via the lateral tail vein. Because intravenous injection of diabetic mice with a 1-mg/kg dose of AMB proved to be toxic (21), we chose to administer both drugs twice daily (b.i.d.) at the same total dose (e.g., AMB and CAS at 1 mg/kg/day were given as 0.5 mg/kg b.i.d.). This dosing regimen eliminated the infusion toxicity associated with AMB and showed no toxicity of CAS (21). Therapy was initiated either 24 h after infection and continued for 4 days (delayed therapy) or 24 h prior to infection with a repeat dose given immediately prior to infection (prophylaxis). In both therapy regimens, infected untreated control mice received vehicle alone. The primary endpoint for efficacy was the time of survival, and tissue fungal burden was assessed as a secondary endpoint.

Quantitation of tissue fungal burden in target organs and histopathological examination. At selected times after infection, mice were euthanized by pentobarbital administration (300 mg/kg intraperitoneally) and the organs were removed and weighed. To directly compare the CFU counts with the values obtained by quantitative PCR (qPCR), the kidneys were cut in half and the fungal burden was quantified by either CFU or qPCR analysis. For all other tissue fungal burden studies, the organs were evaluated solely by qPCR. Additionally, for histopathological analysis, the kidneys and brains were collected from infected mice at 48 h postinfection and fixed in 10% zinc formalin. Fixed tissues were embedded in paraffin, and 5-µm sections were stained with periodic acid-Schiff for light microscopy examination.

To measure the CFU in infected tissues, the harvested organs were homogenized with a Pro 250 handheld tissue homogenizer (Pro Scientific, Inc., Monroe, Conn.) on setting 5. Homogenized tissues were serially diluted in 0.85% saline, and homogenates were spread on PDA plates containing 50 µg of chloramphenicol per ml. The colonies present after 24 h at room temperature were counted, and values were expressed as log₁₀ CFU per gram of tissue. For qPCR analysis, the samples were homogenized as described previously (4), except that the tissue and hyphae were mechanically disrupted by vigorous agitation in a Mixer Mill 300 instrument (QIAGEN, Valencia, Calif.) at 1,800 oscillations per min (three times for 30 s each time), with 1-min pauses between bursts. DNA, which was extracted as described previously (4), was stored at -20°C. Oligonucleotide amplification primers and a dual-labeled fluorogenic oligonucleotide hybridization probe complementary to the *R. oryzae* 18S rRNA gene (GenBank accession no. AF113440) were designed with Primer Express software (version 1.5; Applied Biosystems) and synthesized by Applied Biosystems or Integrated DNA Technologies (Coralville, Iowa). The sequences of these oligonucleotides are as follows: (i) sense amplification primer, 5'-GCGGATCGCATGGCC-3'; (ii) antisense amplification primer, 5'-CCATGATAGGGCAGAAAATCG-3'; and (iii) hybridization probe, 5'-FAM-TGTGTCGGCGACGGTCCAC-TAMRA-3' (where FAM is 6-carboxyfluorescein and TAMRA is 6-carboxyethylrhodamine). The qPCRs were performed as described previously (4).

Differences in DNA recovery between samples were normalized by quantifying a nonmurine, nonfungal DNA sequence on a plasmid which was added to the saline used to homogenize all samples. The plasmid bears a 3-kb fragment containing the protein-coding region of *Eimeria tenella* *PKG* cDNA (GenBank accession no. AF411961). After homogenization and DNA isolation, the samples were analyzed by qPCR with the following primers and probe specific for the *PKG* gene sequence: (i) sense amplification primer, 5'-AGGGCTTTGTGCA CGAC-3'; (ii) antisense amplification primer, 5'-TCCACCTCGGGACTGTTT G-3'; and (iii) hybridization probe, 5'-FAM-TGCTACTGTTGCAGACGCC GCT-TAMRA-3'.

qPCR quantitation of the *PKG* target sequence allows an estimate of the recovery of DNA from crude homogenate through the final DNA sample to be made. The percent recovery of *PKG* DNA is calculated for each experimental sample and is used to normalize each qPCR datum point for the *R. oryzae* 18S rRNA gene target.

Statistical analysis. Survival data were analyzed by the nonparametric log-rank test. Differences in tissue fungal burdens in the infected organs were compared by the nonparametric Steel test for multiple comparisons. Correlations were calculated by the nonparametric Spearman rank sum test. *P* values of <0.05 were considered significant.

| | |
|-----------------------------------|--|
| <i>S. cerevisiae</i> Fks1p (1104) | NQDNYLEECLKIRSVLAEFEELNVEQVNPYAPGLRYEEQTTN-HPVAIVGAREYIFSENSGVLDVAAGKEQ |
| <i>S. cerevisiae</i> Fks2p (1123) | NQDNYLEECLKIRSVLAEFEELGIEQIHPYTPGLKYEDQSTN-HPVAIVGAREYIFSENSGVLDVAAGKEQ |
| <i>C. albicans</i> Fks1p (1107) | NQDNYLEECLKIRSVLAEFEEMNVEHVNPYAPNLKSEDNNTKKDPVAVLGAREYIFSENSGVLDVAAGKEQ |
| <i>C. neoformans</i> Fks1p (998) | NQDNYLEECLKIRNVLGEFEFKVSTQSPYAAQG---HADFAKFPVAILGAREYIFSENIGILGDI AAGKEQ |
| <i>A. fumigatus</i> Fksp (1139) | NQDNYLEECLKIRSVLAEFEELTTDNVSPYTPG----IPSTNTNPVAILGAREYIFSENIGVLDVAAGKEQ |
| <i>R. oryzae</i> Fksp | NQD**LEECLKIRNVLGEFEVLEPIQESPYSPS---YQKSNSSPVAIVGAREYIFSENIGILGDAAGKEQ |
| | |
| <i>S. cerevisiae</i> Fks1p (1175) | TFGTLFARTLSQIGGKLYGHPDFINATFMTTRGGVSKAQKGLHLNEDIYAGMNAVLGRGRIKHCEYYQCG |
| <i>S. cerevisiae</i> Fks2p (1194) | TFGTLFARTLAQIGGKLYGHPDFINATFMTTRGGVSKAQKGLHLNEDIYAGMNAVLGRGRIKHCEYYQCG |
| <i>C. albicans</i> Fks1p (1179) | TFGTLFARTLAQIGGKLYGHPDFLNATFMTTRGGVSKAQKGLHLNEDIYAGMNAVLGRGRIKHCEYYQCG |
| <i>C. neoformans</i> Fks1p (1067) | TFGTLAARSLSYIGGKLYGHPDFLNAIYMNTRGGVSKAQKGLHLNEDIYAGMNAVLGRGRIKHCEYYQCG |
| <i>A. fumigatus</i> Fksp (1207) | TFGTLFARTLAQIGGKLYGHPDFLNGIFMTTRGGISKAQKGLHLNEDIYAGMNAVLGRGRIKHCEYYQCG |
| <i>R. oryzae</i> Fksp | TFGTLTQRIMAKSGGKLYGHPDFLNAIYMNTRGGVSKAQKGLHLNEDIYAGMNSFIRGGRIKHTEYY*CG |

FIG. 1. Amino acid sequences derived from the *FKS* genes of *S. cerevisiae* (*FKS1*, GenBank accession no. U12893; *FKS2*, GenBank accession no. U16783), *C. albicans* (GenBank accession no. D88815), *C. neoformans* (GenBank accession no. AF102882), and *A. fumigatus* (GenBank accession no. U79728) were aligned with the putative *R. oryzae* Fksp amino acid sequence. Gray shading represents amino acids that share identity among all Fks proteins shown. Asterisks denote positions whose sequences could not be determined due to the incorporation of inosine in the degenerate primers used to clone the *R. oryzae* *FKS* fragment.

RESULTS

***R. oryzae* FKS gene.** In all fungi examined to date, the presence of an *FKS* gene has been predictive of GS activity, and there is a high degree of homology between *FKS* genes from diverse fungal genera (9). We used degenerate primers homologous to conserved residues in a number of known *FKS* sequences in an effort to identify an *FKS* homolog in *R. oryzae*. A fragment similar in size to the equivalent region of *A. fumigatus* *FKS* (~400 bp) was amplified by PCR, cloned, and sequenced. The predicted amino acid sequence revealed a portion of a unique Fks protein with a high degree of conservation (64%) to other members of the Fksp family (Fig. 1). The *R. oryzae* *FKS* fragment was used as a probe for total *R. oryzae* genomic DNA on a Southern blot, and only a single *FKS* homolog was detected under conditions of high stringency (data not shown).

***R. oryzae* membranes contain CAS-susceptible GS activity.** Fungal GS is an enzyme complex associated with the plasma membrane. To look for GS activity in *R. oryzae*, crude membranes prepared from growing mycelium were incubated with the GS substrate UDP-glucose and evaluated for the synthesis of a TCA-insoluble product. The activity in crude membranes was both time and protein dependent. As expected for authentic 1,3- β -D-glucan, the radiolabeled product of the *R. oryzae* GS reactions was 100% soluble in dilute base, partially soluble (30.5%) in dilute acid, and susceptible to digestion with exo-1,3- β -D-glucanase (data not shown). The GS activity in crude *R. oryzae* membranes was inhibited by CAS in a dose-dependent manner, with an estimated IC₅₀ of 11.9 μ g/ml.

In vitro inhibition of *R. oryzae* growth by CAS and AMB. The susceptibility of *R. oryzae* strain 99-880 to CAS and AMB was measured in a liquid broth microdilution assay. By using the conditions defined in the NCCLS M38A document (28a), the MIC and the minimum effective concentration of CAS were >16 μ g/ml for this isolate, and the AMB MIC was 0.25 μ g/ml for this isolate.

CAS improves the survival of diabetic mice infected with a small inoculum of *R. oryzae*. The inhibition of *R. oryzae* GS by CAS and the discovery of an *FKS* homolog demonstrate that the drug target is present in this organism. CAS might be effective against *R. oryzae* in vivo, despite the high MIC, espe-

cially given the known constraints of MIC testing with molds (13, 29). The in vivo efficacy of CAS was tested in diabetic ketoacidotic mice infected with *R. oryzae*. Intravenous treatment with AMB (0.5 mg/kg b.i.d.) or CAS (0.5, 2.5, or 5 mg/kg b.i.d.) was initiated 24 h after the mice were infected with 5×10^2 or 5×10^3 spores of *R. oryzae*. At 0.5 mg/kg b.i.d., CAS, but not AMB, improved the survival of mice infected with 5×10^2 spores of *R. oryzae* compared to that of the infected untreated mice ($P = 0.049$) (Fig. 2a). Eighty percent of the diabetic mice treated with CAS at 0.5 mg/kg/day were alive 10 days after infection, whereas 30% of the infected untreated mice were alive at that time. Surprisingly, higher doses of CAS (2.5 or 5 mg/kg b.i.d.) did not improve the rate of survival. Neither CAS nor AMB protected mice from the larger inoculum (5×10^3 spores) of *R. oryzae* (Fig. 2b).

Tissue fungal burden determined by qPCR but not CFU correlates with disease progression in diabetic mice infected with *R. oryzae*. Because of the nature of hyphal growth of filamentous fungi, CFU determination may not accurately measure the fungal biomass in infected tissues (3). We therefore sought to develop a qPCR-based assay, previously used to measure the extent of *A. fumigatus* infection in mice (4), to quantitate the *R. oryzae* burden in murine tissues. We initially quantified the fungal burden in the kidney because the gross appearance of the kidneys in preliminary necropsies was more abnormal than that of the other organs (data not shown). At 6 h postinfection, there were strong correlations between the inoculum and the fungal burden measured by either CFU determination or qPCR ($P < 0.0001$ for both end points; Spearman rank sum correlation value [ρ] = 0.97 for CFU and 0.95 for qPCR) (Fig. 3). The results from the CFU and qPCR analyses strongly correlated with each other at this time point ($P < 0.0001$; $\rho = 0.93$) (Fig. 3c), consistent with the expectation that *R. oryzae* is predominantly present as spores and small germlings rather than long hyphae at 6 h postinfection. By 24 h after infection, the results of both CFU and qPCR analyses still correlated with the inocula and with each other, but to a slightly decreased degree ($P < 0.0001$ and $\rho = 0.91$ for both CFU and qPCR; $P = 0.0001$ and $\rho = 0.89$ for CFU versus qPCR). However, when the mycelial burden was measured at




FIG. 2. Survival of diabetic mice infected with 5×10^2 (a) or 5×10^3 (b) spores of *R. oryzae* and treated with different regimens of AMB, CAS, or vehicle. Treatment was initiated at 24 h postinfection and was given twice daily for a total of 4 days. (a) $n = 10$ mice per group; (b) $n = 12$ mice per group. *, $P < 0.05$ for CAS (0.5 mg/kg b.i.d.) versus the results obtained with placebo; solid line, uninfected and untreated; ■, infected and untreated; ▲, AMB at 0.5 mg/kg b.i.d.; ×, CAS at 0.5 mg/kg b.i.d.; □, CAS at 2.5 mg/kg b.i.d.; ●, CAS at 5.0 mg/kg b.i.d.

48 h, by which time filamentation is expected to have occurred in vivo, there was no correlation between CFU values and the inocula ($P = 0.2$) or between the CFU and qPCR values ($P = 0.1$; $\rho = 0.39$). In contrast, the results of qPCR analysis still correlated strongly with the burden in tissue from the increasing inocula ($P = 0.0001$, $\rho = 0.9$) (Fig. 3). Infection in the kidneys progressed between 6 and 48 h postinfection at the three largest inocula ($\geq 5 \times 10^4$ CFU/ml), but only when qPCR values (Fig. 3b) and not CFU values (Fig. 3a) were considered. Histopathology of the brains and kidneys of mice infected with 5×10^5 spores of *R. oryzae* confirmed the presence of active infection at 48 h, in line with the qPCR results (Fig. 3d).

We assessed the tissue distribution and progression of *R. oryzae* disease in this model using qPCR. Mice infected with 5×10^4 spores of *R. oryzae* were euthanized 72 h postinfection; and the brains, kidneys, spleens, livers, and lungs were collected and evaluated for their fungal burdens. The heaviest fungal load in diabetic mice infected with *R. oryzae* 99-880 was in the brain; and secondary target organs included the kidney, spleen, liver, and lung (Table 1). In another study, animals infected with 10^5 spores were either monitored for survival or

assessed for the fungal burden in their brains and kidneys by qPCR. The infections in both organs progressed between days 1 and 3 postinfection, and all deaths in the survival group occurred on day 3 postinfection (Fig. 4). The infections in the brains were consistently more severe than those in the kidneys, and an apparent peak of brain burden coincident with the onset of mortality was observed.

Prophylactic treatment but not delayed therapy with CAS reduces the fungal burden. Because CAS showed promising activity in protecting mice from *R. oryzae* infection, we investigated the effect of drug treatment on fungal burden. On the basis of our earlier results (Table 1), the brains and kidneys were chosen for assessment of the tissue burden by qPCR.

Mice were infected with 5×10^3 spores of *R. oryzae*, and treatment with AMB or CAS at 0.5 mg/kg b.i.d. was initiated for 2 days either 24 h prior to infection (prophylactic treatment) or 24 h after infection (delayed treatment). Compared to the outcome for untreated controls, prophylactic treatment with AMB or CAS significantly reduced the brain fungal burden by >1.7 log₁₀ spore equivalents at 24 h following administration of the last dose of therapy ($P \leq 0.005$) (Table 2). The fungal burdens in kidneys from the same animals trended to lower levels with AMB or CAS therapy ($P = 0.15$ and 0.1, respectively). The tissue fungal burdens of mice treated prophylactically were no longer different from those of the untreated controls by 48 h after administration of the last dose of CAS (Table 2). In contrast to prophylactic treatment, delayed therapy with AMB and CAS did not significantly reduce the tissue fungal burden in the kidneys or brain (data not shown).

DISCUSSION

There have been no prospective randomized trials to define the optimal antifungal therapy for zygomycosis, and AMB remains the only antifungal agent approved for the treatment of this infection (22, 35). However, given the unacceptably high rate of mortality from zygomycosis ($>50\%$), clinicians are in dire need of novel therapeutic strategies for this disease. In the past decade, new therapies that may be useful for the treatment of zygomycosis have become available. For example, high-dose lipid formulations of AMB have been demonstrated to be efficacious in both a murine model of *R. oryzae* infection (21) and individual patients (15, 19). Studies have also suggested that the investigational triazole posaconazole may be effective (5, 6, 36). The potential activities of echinocandins against zygomycosis have remained relatively unexplored, due in part to their unimpressive in vitro activities against zygomycetes.

In this study, we demonstrated that the most common causative organism of zygomycosis, *R. oryzae*, possesses a genetic homolog of *FKS*, the molecular target of echinocandin and a subunit of GS. CAS was shown to inhibit *R. oryzae* GS activity. Given the presence of the target enzyme in *R. oryzae* and the known difficulties of interpreting echinocandin MICs for molds (14, 29), we tested the efficacy of CAS at 0.5, 2.5, and 5 mg/kg b.i.d. for the treatment of zygomycosis in vivo. These doses were chosen on the basis of the findings of previous studies of *Candida*, *Aspergillus*, and *Histoplasma* infections (1, 4, 16, 17, 23, 24). The 0.5-mg/kg b.i.d. dose approximates the normal dose in humans (a 70-mg load, followed by 50 mg/day) (17). As




FIG. 3. qPCR measurement better reflects progression of *R. oryzae* infection in kidneys than CFU quantitation. Log₁₀ CFU (a) and log₁₀ spore equivalents (b) per gram of kidney tissue as functions of the inoculum at various time points after infection are shown. The limit of detection for the qPCR assay is 1.99 log₁₀ spore equivalents per gram of kidney tissue. Data are displayed as medians ± interquartile ranges. (c) Log₁₀ CFU (y axis) versus log₁₀ spore equivalents (x axis) per gram of kidney tissue at various time points (*n* = 5 mice per group). ρ was determined by the Spearman rank sum test. *, *P* < 0.05. (d) Periodic acid-Schiff staining of brain and kidney tissues from diabetic mice infected for 48 h with 5 × 10⁵ spores of *R. oryzae*. Arrows indicate *R. oryzae* hyphae in tissue. Magnifications, ×400.

well, the levels achievable in serum with the 2.5-mg/kg b.i.d. dose are approximately 20 to 30 μg/ml in mice (32) and therefore are in excess of the IC₅₀ for the *R. oryzae* GS enzyme. Finally, because *R. oryzae* is notoriously resistant to antifungal therapy, we also tested a dose higher than that evaluated previously (5 mg/kg b.i.d.), and the dose was found to be nontoxic in our preliminary experiments (data not shown). We found that one CAS dosing regimen (0.5 mg/kg b.i.d.) improved the rate of survival of diabetic ketoacidotic mice infected with a small inoculum (5 × 10² spores) of *R. oryzae*. There was a surprising inverse dose-response relationship for CAS in this study, with higher doses failing to improve survival. The reason for this inverse dose-response relationship is unclear, but it may be a phenomenon similar to the Eagle effect seen with β-lactams and other antibiotics, in which extremely high concentrations of drug are less microbicidal than lower concentrations (25, 34). There have been other reports of an inverse

dose-response relationship for the antifungal activities for echinocandins. For example, more than 15 years ago, cilofungin demonstrated worse in vitro activity against *Candida* spp. at higher concentrations (18). More recently, a similar in vitro phenomenon was described for CAS against *C. albicans* in the context of biofilm formation (30). Finally, Stevens et al. (33) have confirmed the phenomenon of a paradoxical increased

TABLE 1. Distribution of *R. oryzae* burden in infected untreated diabetic mice as determined by qPCR^a

| Tissue | Log ₁₀ spore equivalents/g of tissue |
|--------|---|
| Brain | 6.60 ± 0.07 |
| Kidney | 4.81 ± 0.68 |
| Spleen | 3.84 ± 0.03 |
| Liver | 3.77 ± 0.34 |
| Lung | 3.30 ± 0.49 |

^a Mice (*n* = 5) were infected with 5 × 10⁴ spores of *R. oryzae* and were euthanized at 72 h postinfection. Values are means ± standard errors.




FIG. 4. Correlation between onset of mortality and increased fungal burden, as determined by qPCR. Diabetic mice were infected with 10⁵ *R. oryzae* spores, and parallel groups of mice were either monitored for survival (*n* = 8) or euthanized for measurement of kidney and brain tissue fungal burdens. Tissue fungal burden values are presented as means ± standard errors of log₁₀ spore equivalents per gram of tissue. Values in parentheses represent the numbers of mice used to determine the tissue fungal burdens.

TABLE 2. Effect of prophylaxis with CAS or AMB on *R. oryzae* burden

| Treatment (dose [mg/kg b.i.d.]) | Log ₁₀ spore equivalents/g of tissue at the following times after last dose ^a : | | | |
|------------------------------------|--|--------------------------|-------------|-------------|
| | 24 h | | 48 h | |
| | Kidney | Brain | Kidney | Brain |
| Infected untreated | 4.33 ± 0.13 | 4.74 ± 0.11 | 3.81 ± 0.36 | 6.07 ± 0.39 |
| AMB (0.5) | 3.40 ± 0.42 | 2.26 ± 0.14 ^b | 2.61 ± 0.37 | 5.72 ± 0.52 |
| CAS (0.5) | 3.56 ± 0.31 | 2.96 ± 0.23 ^b | 3.67 ± 0.58 | 6.43 ± 0.32 |

^a Values are means ± standard errors (*n* = 7).

^b *P* < 0.05 compared to the results for the control.

growth of *C. albicans* at higher in vitro concentrations of CAS. The in vivo significance of these in vitro data is underscored by the findings from a murine model of CAS treatment for pulmonary aspergillosis (40) that are similar to our results with *R. oryzae*.

As an additional marker of efficacy, we evaluated the impact of CAS therapy on the tissue burden of *R. oryzae*. During infection, *R. oryzae* propagates in the filamentous form through apical extension (38). The relationship between CFU and fungal mass is not well defined for most molds, which grow as multicellular mycelia in the organs of infected hosts (4, 38). We found that the *R. oryzae* CFU values in the kidneys of infected mice did not increase with time, and there was no correlation between the initial inoculum and the fungal load at a time when hyphal growth is prevalent in tissues (48 h postinfection). To circumvent this problem, we developed a qPCR-based assay to quantify *R. oryzae* in the tissues of infected mice. Previous work with *A. fumigatus* suggested that qPCR could be used to measure the progression of infection and the efficacy of antifungal therapy in animal models of disease (4). In contrast to CFU measurement, the fungal burden assessed by qPCR correlated with the increasing inoculum at all times tested and also temporally paralleled the rate of mortality. Our results indicate that qPCR values more accurately reflect the *R. oryzae* burden in tissue than CFU values beyond 24 h of infection in mice. Histopathology confirmed the presence of extensive hyphae in the kidneys and brains of mice infected with the largest inocula (5×10^5) at 48 h (Fig. 3d), concordant with the qPCR results and discordant with the CFU results. Therefore, the histopathology findings support the conclusion that qPCR is more accurate for quantitation of the burden of filamentous fungi in tissue beyond 24 h of infection. Of note, although the qPCR results accurately reflected the tissue fungal burden, only a small amount of tissue is actually assessed for fungal burden in the qPCR assay (<1 mg equivalent). As a result, the inoculum required to detect a qPCR signal (1×10^4) was 20-fold greater than the smallest inoculum required to cause death (5×10^2).

Prophylaxis with CAS decreased the burden of *R. oryzae* in the kidneys and brains when it was measured at 24 h posttreatment. However, this therapeutic effect was lost by 72 h posttreatment, at which point the burdens were equivalent in treated and untreated mice. The tissue fungal burden was assessed with inocula larger than those used to assess survival, due to the lower limit of detection of the qPCR assay, which required an inoculum of at least 10^4 spores to permit detection of the fungal burden. Hence, direct comparisons of the effects

of CAS on survival and tissue fungal burden as assessed by qPCR could not be performed in this study.

One possible explanation for the limited activity of CAS is the requirement for a relatively high concentration of drug to inhibit *R. oryzae* GS. Echinocandins inhibit crude GS from susceptible fungi (*A. fumigatus* and *C. albicans*) with IC₅₀s in the nanogram-per-milliliter range (10, 27), which is roughly 1,000-fold lower than the concentration of CAS required to inhibit *R. oryzae* GS synthesis by 50% (~12 μg/ml). However, there was no trend toward superior efficacy with increasing CAS dose in our models of infection, suggesting that incremental increases in GS inhibition might not lead to greater susceptibility in vivo. The role of GS in *R. oryzae* cell wall metabolism is poorly understood. The fungus may form a functional wall in the absence of 1,3-β-D-glucan (i.e., GS may not be essential in *R. oryzae*), or synthesis may be important during one phase of apical growth and dispensable during another. A more thorough characterization of *R. oryzae* GS, and cell wall synthesis in general, is warranted.

In summary, we demonstrated that *R. oryzae* possesses an *FKS* homolog and contains membrane-associated GS activity which can be inhibited by CAS, albeit at relatively high concentrations. Despite unimpressive MICs, therapy with CAS at 0.5 mg/kg b.i.d. resulted in significant improvement in survival during murine zygomycosis caused by a small inoculum of *R. oryzae*. CAS given prophylactically reduced the tissue fungal burden early in the infection, but the protective benefit of CAS was lost with a larger inoculum or at later time points. Finally, assessment of the organ fungal burden by a qPCR assay was superior to CFU measurement for monitoring the progression of *R. oryzae* infection. Although these results do not support a role for CAS as monotherapy against *R. oryzae*, its potential for use in combination therapy with a polyene or azole merits investigation.

ACKNOWLEDGMENTS

This study was supported by a research and educational grant from Merck & Company and a New Investigator Award in Molecular Pathogenic Mycology from the Burroughs Wellcome Fund to A.S.I. A.S.I. is also supported by grant RO3 AI054531 from the National Institute of Allergy and Infectious Diseases. B.S. is supported by Public Health Service grant KO8 AI060641-01.

We thank Jennifer Nielsen Kahn and Ming-Jo Hsu for help with the GS assays and Jennifer Anderson for design of the *PKG*-specific primers and probe.

The research described in this report was conducted in part at the research facilities of the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center.

REFERENCES

1. Abruzzo, G. K., C. J. Gill, A. M. Flattery, L. Kong, C. Leighton, J. G. Smith, V. B. Pikounis, K. Bartizal, and H. Rosen. 2000. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. *Antimicrob. Agents Chemother.* 44:2310–2318.
2. Arikian, S., M. Lozano-Chiu, V. Paetznick, and J. H. Rex. 2002. In vitro synergy of caspofungin and amphotericin B against *Aspergillus* and *Fusarium* spp. *Antimicrob. Agents Chemother.* 46:245–247.
3. Bowman, J., A. Ibrahim, J. Anderson, P. Liberator, V. Avanesian, J. J. Edwards, and C. Douglas. 2002. Quantitation of mycelial fungal pathogens by PCR, abstr. M-910. Abstr. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
4. Bowman, J. C., G. K. Abruzzo, J. W. Anderson, A. M. Flattery, C. J. Gill, V. B. Pikounis, D. M. Schmatz, P. A. Liberator, and C. M. Douglas. 2001. Quantitative PCR assay to measure *Aspergillus fumigatus* burden in a murine

- model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. *Antimicrob. Agents Chemother.* **45**:3474–3481.
5. **Dannaoui, E., J. F. Meis, D. Loebenberg, and P. E. Verweij.** 2003. Activity of posaconazole in treatment of experimental disseminated zygomycosis. *Antimicrob. Agents Chemother.* **47**:3647–3650.
 6. **Dannaoui, E., J. Meletiadis, J. W. Mouton, J. F. Meis, and P. E. Verweij.** 2003. In vitro susceptibilities of zygomycetes to conventional and new antifungals. *J. Antimicrob. Chemother.* **51**:45–52.
 7. **Del Poeta, M., M. C. Cruz, M. E. Cardenas, J. R. Perfect, and J. Heitman.** 2000. Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against *Cryptococcus neoformans*. *Antimicrob. Agents Chemother.* **44**:739–746.
 8. **Denning, D. W.** 1997. Echinocandins and pneumocandins—a new antifungal class with a novel mode of action. *J. Antimicrob. Chemother.* **40**:611–614.
 9. **Douglas, C. M.** 2001. Fungal beta(1,3)-D-glucan synthesis. *Med. Mycol.* **39**(Suppl. 1):55–66.
 10. **Douglas, C. M., J. A. D'Ippolito, G. J. Shei, M. Meinz, J. Onishi, J. A. Marrinan, W. Li, G. K. Abruzzo, A. Flattery, K. Bartizal, A. Mitchell, and M. B. Kurtz.** 1997. Identification of the *FKS1* gene of *Candida albicans* as the essential target of 1,3-β-D-glucan synthase inhibitors. *Antimicrob. Agents Chemother.* **41**:2471–2479.
 11. **Douglas, C. M., J. A. Marrinan, W. Li, and M. B. Kurtz.** 1994. A *Saccharomyces cerevisiae* mutant with echinocandin-resistant 1,3-β-D-glucan synthase. *J. Bacteriol.* **176**:5686–5696.
 12. **Edwards, J., Jr.** 1989. Zygomycosis, p. 1192–1199. In P. Hoepflich and M. Jordan (ed.), *Infectious disease*, 4th ed. J. B. Lippincott Co., Philadelphia, Pa.
 13. **Espinel-Ingroff, A.** 1999. Problems of antifungal in vitro testing in *Aspergillus fumigatus*. *Contrib. Microbiol.* **2**:139–148.
 14. **Espinel-Ingroff, A.** 2003. Utility of mould susceptibility testing. *Curr. Opin. Infect. Dis.* **16**:527–532.
 15. **Gonzalez, C. E., D. R. Couriel, and T. J. Walsh.** 1997. Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor. *Clin. Infect. Dis.* **24**:192–196.
 16. **Graybill, J. R., R. Bocanegra, L. K. Najvar, S. Hernandez, and R. A. Larsen.** 2003. Addition of caspofungin to fluconazole does not improve outcome in murine candidiasis. *Antimicrob. Agents Chemother.* **47**:2373–2375.
 17. **Hajdu, R., R. Thompson, J. G. Sundelof, B. A. Pelak, F. A. Bouffard, J. F. Dropinski, and H. Kropp.** 1997. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). *Antimicrob. Agents Chemother.* **41**:2339–2344.
 18. **Hall, G. S., C. Myles, K. J. Pratt, and J. A. Washington.** 1988. Cilofungin (LY121019), an antifungal agent with specific activity against *Candida albicans* and *Candida tropicalis*. *Antimicrob. Agents Chemother.* **32**:1331–1335.
 19. **Herbrecht, R., V. Letscher-Bru, R. A. Bowden, S. Kusne, E. J. Anaissie, J. R. Graybill, G. A. Noskin, B. A. Oppenheim, E. Andres, and L. A. Pietrelli.** 2001. Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. *Eur. J. Clin. Microbiol. Infect. Dis.* **20**:460–466.
 20. **Hussain, S., N. Salahuddin, I. Ahmad, I. Salahuddin, and R. Joorna.** 1995. Rhinocerebral invasive mycosis: occurrence in immunocompetent individuals. *Eur. J. Radiol.* **20**:151–155.
 21. **Ibrahim, A. S., V. Avanesian, B. Spellberg, and J. E. Edwards, Jr.** 2003. Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with *Rhizopus oryzae*. *Antimicrob. Agents Chemother.* **47**:3343–3344.
 22. **Ibrahim, A. S., J. E. J. Edwards, and S. G. Filler.** 2003. Zygomycosis, p. 241–251. In W. E. Dismukes, P. G. Pappas, and J. D. Sobel (ed.), *Clinical mycology*. Oxford University Press, New York, N.Y.
 23. **Ju, J. Y., C. Polhamus, K. A. Marr, S. M. Holland, and J. E. Bennett.** 2002. Efficacies of fluconazole, caspofungin, and amphotericin B in *Candida glabrata*-infected p47^{phox}^{-/-} knockout mice. *Antimicrob. Agents Chemother.* **46**:1240–1245.
 24. **Kohler, S., L. J. Wheat, P. Connolly, C. Schnizlein-Bick, M. Durkin, M. Smedema, J. Goldberg, and E. Brizendine.** 2000. Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. *Antimicrob. Agents Chemother.* **44**:1850–1854.
 25. **Kondo, N., K. Kuwahara-Arai, H. Kuroda-Murakami, E. Tateda-Suzuki, and K. Hiratsmu.** 2001. Eagle-type methicillin resistance: new phenotype of high methicillin resistance under *mec* regulator gene control. *Antimicrob. Agents Chemother.* **45**:815–824.
 26. **Krishnarao, T. V., and J. N. Galgiani.** 1997. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against *Candida* species and *Cryptococcus neoformans*. *Antimicrob. Agents Chemother.* **41**:1957–1960.
 27. **Kurtz, M. B., I. B. Heath, J. Marrinan, S. Dreikorn, J. Onishi, and C. Douglas.** 1994. Morphological effects of lipopeptides against *Aspergillus fumigatus* correlate with activities against (1,3)-β-D-glucan synthase. *Antimicrob. Agents Chemother.* **38**:1480–1489.
 28. **Kwon-Chung, K. J., and J. E. Bennett.** 1992. Mucormycosis, p. 524–559. In *Medical mycology*. Lea & Febiger, Philadelphia, Pa.
 - 28a. **National Committee for Clinical Laboratory Standards.** 2002. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Approved standard M38-A. NCCLS, Wayne, Pa.
 29. **Pfaller, M. A., F. Marco, S. A. Messer, and R. N. Jones.** 1998. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of *Aspergillus*, *Fusarium*, *Rhizopus*, and other filamentous fungi. *Diagn. Microbiol. Infect. Dis.* **30**:251–255.
 30. **Ramage, G., K. VandeWalle, S. P. Bachmann, B. L. Wickes, and J. L. Lopez-Ribot.** 2002. In vitro pharmacodynamic properties of three antifungal agents against preformed *Candida albicans* biofilms determined by time-kill studies. *Antimicrob. Agents Chemother.* **46**:3634–3636.
 31. **Ribes, J. A., C. L. Vanover-Sams, and D. J. Baker.** 2000. Zygomycetes in human disease. *Clin. Microbiol. Rev.* **13**:236–301.
 32. **Sandhu, P., X. Xu, P. J. Bondiskey, S. K. Balani, M. L. Morris, Y. S. Tang, A. R. Miller, and P. G. Pearson.** 2004. Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys. *Antimicrob. Agents Chemother.* **48**:1272–1280.
 33. **Stevens, D. A., M. Espiritu, and R. Parmar.** 2004. Paradoxical effect of caspofungin: reduced activity against *Candida albicans* at high drug concentrations. *Antimicrob. Agents Chemother.* **48**:3407–3411.
 34. **Stratton, C. W., C. Liu, H. B. Ratner, and L. S. Weeks.** 1987. Bactericidal activity of deptomycin (LY146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studies. *Antimicrob. Agents Chemother.* **31**:1014–1016.
 35. **Sugar, A. M.** 1995. Agent of mucormycosis and related species, p. 2311–2321. In G. Mandell, J. Bennett, and R. Dolin (ed.), *Principles and practices of infectious diseases*, 4th ed. Churchill Livingstone, New York, N.Y.
 36. **Sun, Q. N., L. K. Najvar, R. Bocanegra, D. Loebenberg, and J. R. Graybill.** 2002. In vivo activity of posaconazole against *Mucor* spp. in an immunosuppressed-mouse model. *Antimicrob. Agents Chemother.* **46**:2310–2312.
 37. **Tang, C. M., J. Cohen, and D. W. Holden.** 1992. An *Aspergillus fumigatus* alkaline protease mutant constructed by gene disruption is deficient in extracellular elastase activity. *Mol. Microbiol.* **6**:1663–1671.
 38. **Waldorf, A. R., C. Halde, and N. A. Vedros.** 1982. Murine model of pulmonary mucormycosis in cortisone-treated mice. *Sabouraudia* **20**:217–224.
 39. **Waldorf, A. R., N. Ruderman, and R. D. Diamond.** 1984. Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against *Rhizopus*. *J. Clin. Invest.* **74**:150–160.
 40. **Wiederhold, N. P., D. P. Kontoyiannis, J. Chi, R. A. Prince, V. H. Tam, and R. E. Lewis.** 2004. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. *J. Infect. Dis.* **190**:1464–1471.